פרסוגרל טבע 10 מ"ג - Prasugrel teva 10 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||
|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | B01AC Platelet aggregation inhibitors excluding heparin | ||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||
| ×ת×××× | Prasugrel Teva, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI). The increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had TIA/CVA in the past and in those above the age of 75 or weight below 60 kg. | ||||||
| |||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 ××× ×¢××× ×ר××¤× Â | ||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| פרס×××¨× ×××¢ 10 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL |
| ×©× ××¢× ×ר×ש×× | ABIC MARKETING LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 6/2018. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 25/07/2021 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־6 ביולי 2024 ב־15:40